Showing results (51-60 of 165) with videos related to
Sort By:
Pageof 17
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 6, 2010
Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!Paul G Ambrose, Sujata M Bhavnani, Evelyn J Ellis-Grosse, et al.Antimicrobial Agents and Chemotherapy|December 6, 2017
Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing DesignAlexander J Lepak, Miao Zhao, Brian VanScoy, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
The pharmacokinetic and pharmacodynamic profile of tigecyclineAlison K Meagher, Paul G Ambrose, Thaddeus H Grasela, et al.Current Opinion in Pharmacology|November 3, 2017
β-Lactamase inhibitors: what you really need to knowPaul G Ambrose, Olga Lomovskaya, David C Griffith, et al.Antimicrobial Agents and Chemotherapy|February 6, 2024
<i>In vivo</i> pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse modelAlexander J Lepak, Brian VanScoy, Chris Rubino, et al.Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Toll-like receptor 5 (TLR5), IL-1β secretion, and asparagine endopeptidase are critical factors for alveolar macrophage phagocytosis and bacterial killingDelphyne Descamps, Mathieu Le Gars, Viviane Balloy, et al.Diagnostic Microbiology and Infectious Disease|August 18, 2005
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agentAlison K Meagher, Paul G Ambrose, Thaddeus H Grasela, et al.Diagnostic Microbiology and Infectious Disease|August 18, 2005
Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamasesRonald N Jones, William A Craig, Paul G Ambrose, et al.Antimicrobial Agents and Chemotherapy|June 9, 2016
Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection ModelBrian VanScoy, Jennifer McCauley, Sujata M Bhavnani, et al.Antimicrobial Agents and Chemotherapy|December 27, 2005
Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variablesJeffrey P Hammel, Sujata M Bhavnani, Ronald N Jones, et al.Pageof 17